News Breaks |
|
|
| February 1, 2013 |
| 09:25 EDT |  | VVUS, TSN, DELL, ALKS, MCK, GDOT, MRK, LTM, NFLX, CTRP, ADNC, ELN, MAT | On The Fly: Pre-market Movers
UP AFTER EARNINGS/GUIDANCE: Audience (ADNC), up 30%... Tyson Foods (TSN), up 3.3%... Ctrip.com (CTRP), up 8.5%... Green Dot (GDOT), up 6.5%... ALSO HIGHER: Dell (DELL), up 6% after Reuters says 'go private' deal may happen Monday... VIVUS (VVUS), up 5.7% after study published on weight loss drug improving cardiovascular disease risk factors... Netflix (NFLX), up 3.3% after Morgan Stanley raises price target on shares to $200... DOWN AFTER EARNINGS/GUIDANCE: Merck (MRK), down 2.9%... McKesson (MCK), down 2.1%... Mattel (MAT), down 1.7%... Life Time Fitness (LTM), down 16.4%... ALSO LOWER: Alkermes (ALKS), down 5.9% after Elan (ELN) to sell remaining stake, shares downgraded to Neutral at BofA Merrill Lynch. |
|
|
News For DELL;ADNC;MRK;TSN;CTRP;GDOT;VVUS;NFLX;MCK;MAT;LTM;ALKS;ELN From The Last 14 Days Check below for free stories on DELL;ADNC;MRK;TSN;CTRP;GDOT;VVUS;NFLX;MCK;MAT;LTM;ALKS;ELN the last two weeks. |
|
|
| May 21, 2013 |
| 18:56 EDT | | MRK | On The Fly: After Hours Movers
 Subscribe for More Information |
|
| 17:03 EDT | | MRK | Merck announces $5B share repurchase
Subscribe for More Information |
|
| 17:01 EDT | | MRK | Merck announces $5B accelerated share repurchase
Subscribe for More Information |
|
| 13:17 EDT | | NFLX | Netflix says Ricky Gervais' original series to debut September 12
Subscribe for More Information |
|
| 10:00 EDT |  | MAT | On The Fly: Analyst Initiation Summary
Subscribe for More Information |
|
| 07:44 EDT |  | MRK | Sachs Associates to host a forum
Subscribe for More Information |
|
| 07:07 EDT |  | ELN | Theravance pullback on Elan bid a buying opportunity, says Piper Jaffray
Subscribe for More Information |
|
| May 20, 2013 |
| 17:49 EDT |  | MRK | Merck sleep drug effective, dosages questioned, WSJ reports
Subscribe for More Information |
|
| 16:55 EDT | | DELL | S&P lowers Dell ratings to 'BBB' from 'A-', remains on watch negative
Standard & Poor's Ratings Services lowered its corporate credit and senior unsecured debt ratings on Dell to 'BBB' from 'A-', and its commercial paper rating to 'A-2' from 'A-1'. All ratings remain on CreditWatch, where they were placed with negative implications on Feb. 5. The initial CreditWatch listing reflected S&P's assessment that the $24.4B going private transaction, which includes a substantial portion of debt financing, will materially degrade Dell's financial risk profile, which S&P currently view as modest. Although Carl Icahn submitted a non-binding alternative acquisition proposal, the Michael Dell and Silver Lake Partners LBO proposal remains the only transaction that has been approved by Dell's board of directors. S&P's review of the LBO transaction terms and the company's ownership, business and financial strategy may also result in a downward revision of its assessment of Dell's business risk profile. |
|
| 16:15 EDT | | MAT | Mattel initiated with an Overweight at Piper Jaffray
Subscribe for More Information |
| |
| 13:03 EDT | | ELN | Elan advises holders to take no action related to Royalty offer
Subscribe for More Information |
|
| 11:46 EDT | | ELN | Royalty Pharma ups offer for Elan to $12.50 per share in cash
Royalty Pharma announced that it raised its takeover offer for Elan to $12.50 per share in cash. The increased offer is fully financed, cash confirmed and not conditional on due diligence, the company added, while saying the $1.00 per share net cash right has been eliminated. Royalty Pharma added that it has reserved its right to waive down the acceptance threshold for the increased offer from 90% to 50% plus one Elan share. Reference Link |
|
| 11:43 EDT | | ELN | Elan rallies 3.6% to $12.10 after Royalty Pharm raises buyout offer
|
|
| 11:42 EDT | | ELN | Royalty Pharma raises offer for Elan to $12.50 per share in cash
Subscribe for More Information |
|
| 11:14 EDT | | DELL | Dell to deliver public cloud through partner ecosystem
Subscribe for More Information |
|
| 07:32 EDT | | MRK | Society for Information Display / IHS to host a conference
Display Week 2013 is being held in Vancouver, British Columbia on May 19-24. |
|
| 07:03 EDT | | DELL | Dell committee says cannot evaluate Icahn proposal without more information
Subscribe for More Information |
|
| 05:54 EDT | | ELN | Elan announces transactions to transform company, $200M share repurchase plan
Elan announces a series of transactions designed to decisively transform and advance the company. Upon shareholder approval, the totality of these strategically driven decisions, in addition to the Theravance royalty participation agreement and dividend pass through announced last week and the previously completed Tysabri transaction, will form a dynamic and unique business foundation for Elan in the years ahead. Elan will acquire 100% of AOP Orphan Pharmaceuticals and upon close Elan will pay EUR 263.5M for the company, comprised of EUR 175.7M in cash and EUR 87.8M of Elan ordinary shares. In addition, there will be potential cash milestone payments of up to EUR 270M on the advancement of certain late stage clinical programs. Elan has completed the first step in its investment in Newbridge by paying $40M in exchange for 48% of the total fully diluted capitalization of the company. In addition, Elan has appointed two directors to the board of Newbridge. Elan has the option to purchase the remaining stake in Newbridge by 2015 for a sum of $244M. Elan will commit $70M to the new entity upfront, plus up to a potential future $8M, for an 18% minority equity position, royalties in major markets along with additional milestones, and retention of commercial rights in certain territories and markets. The third party equity financial partner will commit $20M for 62% equity position, plus up to a potential future $2M. The remaining 20% equity will be allocated among Speranza management. This allows Elan to eliminate the operating activities associated with the development of the drug, while at the same time maintaining a share of the potential upside. A $200M share repurchse program is planned, details pending. |
|
| 05:22 EDT | | ELN | Elan to host business news update conference call
Subscribe for More Information |
|
| May 17, 2013 |
| 14:03 EDT |  | DELL | Market set to finish week with gains after Cisco results, comments
Subscribe for More Information |
| |
|
|
|
|
